On August 5, 2025, Amgen issued a press release announcing its unaudited results of operations for the 3 and 6 months ended June 30, 2025 and its unaudited financial position as of June 30, 2025.

1. 01

   On August 5, 2025, Amgen issued a press release announcing its unaudited results of operations for the 3 and 6 months ended June 30, 2025 and its unaudited financial position as of June 30, 2025.

2. 02

   The company said the press release included non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development expenses and non-GAAP selling, general and administrative expenses, along with reconciliations to the most directly comparable GAAP financial measures.

3. 03

   Amgen said it computed Free Cash Flow (FCF) by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP, and that it believes FCF provides a further measure of the company's liquidity.

4. 04

   The company said that in calculating non-GAAP financial measures, it excludes from GAAP financial measures acquisition-related expenses, net charges from restructuring and cost savings initiatives, gains and losses on investments in equity securities and certain items associated with legal proceedings.

Analysis scope · Filing body only (exhibits excluded)We analyzed the filing body only. The exhibits exceeded the length limit and were excluded, so figures, financial statements and presentation materials in them were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.